Tuesday, December 18, 2007

A Review of Systemic Retinoid Therapy for Acne. Part 4

Soul contraindications to isotretinoin therapy with appropriate
medication adjustments are outlined by Cunliffe and Stables.

Acne therapy is usually initiated at a dose of 0.5mg/kg daily for
the position 2-4 weeks and then increased to 1.0mg/kg/day for the piece
of cloth of the 20 week pedagogy.
Upon initial intro in 1982, lower dosages of 0.1-0.5mg/kg/day were
given for severe acne with data literary criticism display increased
rates of recurrence compared to the dosages recommended day. The peak
quantity cumulative dose associated with long term, permanent remitment
is 120mg/kg.
Some patients requiring re-treatment after relapse or differential
coefficient mode may require doses of 1.5-2.0 mg/kg/day. Dermatologists
often continue care until the participant role is clinically innocence,
although there is controversy regarding benefits beyond 150mg/kg. Doses
must be adjusted in some cases of concomitant systemic disease.

Inflammatory acne flash is experienced by
approximately 6% of patients in the ordinal period of therapy, and is
clinically significant in about half. Discontinuation of isotretinoin
and trigger of therapy with prednisone at 0.5-1.0mg/kg/day for 2-3
months is the attention of decision making.

Similar doses to
those used in acne are given in acne variants such as mature acne, acne
conglobata, Gram-negative folliculitis, pyoderma faciale and
hidradenitis suppurativa and dissecting cellulitis of the scalp.

A
lower initial dose of 0.25mg/kg/day of isotretinoin, increasing to
1.0mg/kg/day at the end of the 6th week are recommended for acne
fulminans, after a action of prednisone of 0.5-1.0mg/kg for 4-6 weeks.
Rosacea has been shown to respond in doses of 0.5-1.0mg/kg/day in the
past, however, more recent studies showed good efficacy in doses as low
as 10mg/day. Possibleness Side-Effects of Isotretinoin Therapy.



This is a part of article A Review of Systemic Retinoid Therapy for Acne. Part 4 Taken from "Generic Isotretinoin Accutane" Information Blog

No comments: